Acticor Biotech Risk Report

🛡️ Financial & Liquidity

Acticor Biotech has faced significant financial challenges over recent years, culminating in its announcement of liquidation proceedings. The company's financial difficulties have been evident through multiple phases of restructuring and operational halts, reflecting the seriousness of its liquidity issues. These events highlight the critical need for sustainable financial management practices within the biotechnology sector.

• Acticor Biotech announced its liquidation proceedings 🗓 January 5, 2025.
• The company provided an update on its receivership proceedings 🗓 November 6, 2024.
• Acticor halted its phase 2/3 stroke trial for blood thinner due to futility 🗓 July 26, 2024.
• Acticor launched a call for tenders to provide a continuation or sale plan as part of the receivership procedure 🗓 September 12, 2024.
• Acticor initiated a capital increase of a minimum of 7 million euros 🗓 March 14, 2024.

📜 Innovation & R&D

Throughout its operational history, Acticor Biotech has been actively engaged in innovation, particularly in stroke treatment and drug development. Initiatives such as repositioning its drug, Glenzocimab, and launching new trials illustrate the company’s focus on enhancing medical treatments. These efforts underscore the company's commitment to advancing healthcare solutions despite financial setbacks.

• Acticor repositioned Glenzocimab for myocardial infarction treatment 🗓 October 11, 2024.
• First patient was treated in the Liberate trial evaluating Glenzocimab for heart attacks 🗓 February 14, 2024.
• Acticor reported positive data from its phase Ib/IIa acute ischemic stroke trial 🗓 February 22, 2022.
• World's first clinical trial to test Glenzocimab for heart attacks was announced 🗓 November 23, 2022.